BioPharmX Corp. (BPMX), a specialty pharmaceutical company focused on medical dermatology products, announced Tuesday positive results from its Phase 2b clinical trial of BPX-04 for papulopustular rosacea.
In pre-market activity, BioPharmX shares were gaining around 62 percent to trade at $1.43.
BPX-04 is a novel topical gel formulation of fully solubilized minocycline for the treatment of moderate-to-severe papulopustular rosacea.
The randomized, double-blind, vehicle-controlled Phase 2b trial enrolled 206 subjects aged 18 years and above with moderate-to-severe papulopustular rosacea. The study evaluated the safety and efficacy of once daily application of BPX-04, versus a vehicle control over a 12-week treatment period.
The company noted that BPX-04, a 1% minocycline gel, successfully met both the primary and secondary endpoints of the trial. It demonstrated a statistically significant mean change in the number of facial inflammatory lesions and a two-grade improvement to clear or almost clear on the Investigator's Global Assessment or IGA scale from baseline to week 12.
David Tierney, BioPharmX CEO, said, "Based on the efficacy and safety profile, we believe BPX-04 has the potential to be the best-in-class treatment for papulopustular rosacea."
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.